ArticlePhytotherapy research : PTR2025
Nrf2-Mediated Ferroptosis Is Involved in Berberine-Induced Alleviation of Diabetic Kidney Disease.
Article in Phytotherapy research : PTR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Traditional Chinese Medicine-derived berberine-loaded herbzyme ameliorates ulcerative colitis by regulating IL10 and TMAO.Materials today. Bio · 2026Article
- Natural products modulate renal metabolic reprogramming in diabetic kidney disease.Journal of translational internal medicine · 2026Article
- The miR-145-5p/NRF2/SLC7A11 axis regulates ferroptosis-mediated renal tubular epithelial cell injury in diabetic nephropathy.Journal of diabetes investigation · 2026Article
- Emerging Role of Ferroptosis in Diabetes and Associated Complications: When Metabolic Dysregulation Meets Cell Death.Cell proliferation · 2026Review
- Nrf2-Mediated Ferroptosis Is Involved in Berberine-Induced Alleviation of Diabetic Kidney Disease.Phytotherapy research : PTR · 2025Article
- Review
- The pathogenesis of diabetic kidney disease and the therapeutic potential of bioactive substances.Frontiers in pharmacology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Diabetic kidney disease (DKD) is the most common and serious complication of diabetes mellitus. Currently, there is a lack of safe and effective preventive strategies for DKD. The study aimed to explore the preventive effects and potential mechanisms of berberine (BBR) against DKD. In the in vivo experiments, we established a DKD rat model induced by the combination of high-fat diet and streptozotocin to investigate the preventive effect of BBR on DKD. Subsequently, in vitro experiments using human renal tubular epithelial cells (HK-2 cells) were performed to further validate the effect of BBR on renal tubular epithelial cell ferroptosis induced by advanced glycation end products (AGEs). In vivo, we found that BBR improved renal function and attenuated inflammatory cell infiltration, podocyte injury, and iron deposition in renal tissue in DKD rats. In addition, in vitro experiments showed that BBR attenuated HK-2 cell ferroptosis induced by AGEs. We further identified Nrf2 as a direct binding target of BBR by molecular docking and Surface Plasmon Resonance (SPR). Then, immunohistochemistry and Western Blot results demonstrated that BBR could activate the Nrf2 pathway, initiate the endogenous antioxidant system, and inhibit the occurrence of AGEs-induced ferroptosis. Moreover, silencing of Nrf2 by siRNA technology eliminated the protective effect of BBR on AGEs-induced ferroptosis. Collectively, our results supported that BBR could inhibit oxidative stress and ferroptosis by targeting activation of the Nrf2 pathway, thereby delaying the disease progression of DKD, providing a new scientific basis and perspective for the prevention and treatment of DKD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.